Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01443026 · ClinicalTrials.gov registry record · Phase 2

The Effects of Lycopene on High Risk Prostatic Tissue

A Phase 2 study, sponsored by University of Illinois at Chicago.

Completed
Registry status
Phase 2
Development phase
66
Enrollment target

NCT01443026 is a Phase 2 study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 66 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01443026, a Phase 2 study, has completed, sponsored by University of Illinois at Chicago.

COMPLETED
Registry status
Phase 2
Development phase
66 participants
Enrollment target

Study Summary

The purpose of this research study is to compare the effects of a lycopene supplement made from tomatoes to a placebo (a capsule with no active ingredients) in men who have abnormal cells in the prostate, but have not yet had cancer detected. This study will allow us to see if taking lycopene for six months leads to favorable changes in abnormal prostate tissue and in chemicals measured in the blood that go along with a higher risk of developing cancer.

Interventions

  • DRUG Placebo
  • DRUG Lycopene 30mg

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2006-02
Est. Completion 2009-04
Phase Phase 2

Sponsor

University of Illinois at Chicago

430 total trials

What the Registry Record Tells You About NCT01443026

The ClinicalTrials.gov registry entry for NCT01443026 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01443026 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01443026 about?

NCT01443026 is a clinical study titled "The Effects of Lycopene on High Risk Prostatic Tissue". The purpose of this research study is to compare the effects of a lycopene supplement made from tomatoes to a placebo (a capsule with no active ingredients) in men who have abnormal cells in the prostate, but have not yet had cancer detected. This study will allow us to see if taking lycopene for si...

What is the current status of trial NCT01443026?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2006-02. Estimated completion is 2009-04.

What interventions are being tested in trial NCT01443026?

The interventions under investigation include: Placebo (DRUG), Lycopene 30mg (DRUG).

Who is sponsoring clinical trial NCT01443026?

This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.